Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Print publication year: 2010
  • Online publication date: December 2010

Section 2 - Evaluation and management

References

1. de Groat WC, Booth AM. Physiology of the urinary bladder and urethra. Ann Intern Med 1980;92(Pt 2):312–5.
2. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453–66.
3. Fowler CJ. Integrated control of lower urinary tract – clinical perspective. Br J Pharmacol 2006;147(Suppl 2):S14–S24.
4. Norris JP, Staskin DR. History, physical examination, and classification of neurogenic voiding dysfunction. Urol Clin North Am 1996;23:337–43.
5. Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81–8.
6. Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia 1990;28:217–29.
7. Ahlberg J, Edlund C, Wikkelso C, Rosengren L, Fall M. Neurological signs are common in patients with urodynamically verified “idiopathic” bladder overactivity. Neurourol Urodyn 2002;21(1):65–70.
8. Haab F, Richard F, Amarenco G, et al. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire. Urology 2008;71:646–56.
9. Andersson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology 1997;50(6A Suppl):74–84.
10. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78.
11. Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society. BJU Int 2002;90(Suppl 3):11–15.
12. Weiss JP. Nocturia: “do the math”. J Urol 2006;175(3 Pt 2):S16–S18.
13. Beck RP, Arnusch D, King C. Results in treating 210 patients with detrusor overactivity incontinence of urine. Am J Obstet Gynecol 1976;125:593–6.
14. Barry MJ, Fowler FJ, Jr., O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57.
15. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 1995;14:131–9.
16. Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fantl JA. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 1994;3:291–306.
17. Schurch B, Denys P, Kozma CM, et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil 2007;88:646–52.
18. Lubeck DP, Prebil LA, Peeples P, Brown JS. A health related quality of life measure for use in patients with urge urinary incontinence: a validation study. Qual Life Res 1999;8:337–44.
19. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563–74.
20. Costa P, Perrouin-Verbe B, Colvez A, et al. Quality of life in spinal cord injury patients with urinary difficulties. Development and validation of qualiveen. Eur Urol 2001;39:107–13.
21. Bonniaud V, Bryant D, Parratte B, Gallien P, Guyatt G. Qualiveen: a urinary disorder-specific instrument for use in clinical trials in multiple sclerosis. Arch Phys Med Rehabil 2006;87:1661–3.
22. Bonniaud V, Bryant D, Parratte B, Guyatt G. Development and validation of the short form of a urinary quality of life questionnaire: SF-Qualiveen. J Urol 2008;180:2592–8.
23. Acquadro C, Kopp Z, Coyne KS, et al. Translating overactive bladder questionnaires in 14 languages. Urology 2006;67:536–40.
24. Donovan J, Bosch R, Gotoh M, et al. Symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Jersey: Health Publications Ltd; 2005.
25. Homma Y, Ando T, Yoshida M, et al. Voiding and incontinence frequencies: variability of diary data and required diary length. Neurourol Urodyn 2002;21:204–9.
26. Wyman JF, Choi SC, Harkins SW, Wilson MS, Fantl JA. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynecol 1988;71(6 Pt 1):812–17.
27. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56:245–50.
28. Panicker JN, Nagaraja D, Kovoor JM, Nair KP, Subbakrishna DK. Lower urinary tract dysfunction in acute disseminated encephalomyelitis. Mult Scler 2009;15:1118–22.
29. Staskin DR, Zoltan E. Anticholinergics and central nervous system effects: are we confused? Rev Urol 2007;9:191–6.
30. Royal College of Nursing. Catheter Care. RCN Guidance for Nurses. London: Royal College of Nursing; 2008.
31. Fowlis GA, Waters J, Williams G. The cost effectiveness of combined rapid tests (Multistix) in screening for urinary tract infections. J R Soc Med 1994;87:681–2.
32. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:470–7.
33. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70.
34. Department of Health. National service framework for renal services. Part two: chronic kidney disease, acute renal failure and end of life care. London: Department of Health; 2005.
35. Jenkins MA, Brown DJ, Ierino FL, Ratnaike SI. Cystatin C for estimation of glomerular filtration rate in patients with spinal cord injury. Ann Clin Biochem 2003;40(Pt 4):364–8.
36. Carroll P, Albertsen P, Greene K, et al. Prostate-specific antigen best practice statement: 2009 update. American Urological Association Education and Research, Inc., 2009.
37. Blaivas JG, Appell RA, Fantl JA, et al. Standards of efficacy for evaluation of treatment outcomes in urinary incontinence: recommendations of the Urodynamic Society. Neurourol Urodyn 1997;16:145–7.
38. Fowler CJ, O'Malley KJ. Investigation and management of neurogenic bladder dysfunction. J Neurol Neurosurg Psychiatry 2003;74(Suppl 4):iv27–iv31.
39. Stohrer M, Castro-Diaz D, Chartier-Kastler E, et al. Guidelines on neurogenic lower urinary tract dysfunction. Prog Urol 2007;17:703–55.
40. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007;13:915–28.
41. Schafer W, Abrams P, Liao L, et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21:261–74.
42. Blaivas JG, Groutz A. Bladder outlet obstruction nomogram for women with lower urinary tract symptomatology. Neurourol Urodyn 2000;19:553–64.
43. Abrams P, Agarwal M, Drake M, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int 2008;101:989–94.
44. Ruffion A, de Seze M, Denys P, Perrouin-Verbe B, Chartier-Kastler E. Groupe d'Etudes de Neuro-Urologie de Langue Francaise (GENULF) guidelines for the management of spinal cord injury and spina bifida patients. Prog Urol 2007;17:631–3.
45. Podnar S, Vodusek DB. Standardization of anal sphincter electromyography: utility of motor unit potential parameters. Muscle Nerve 2001;24:946–51.
46. Podnar S, Trsinar B, Vodusek DB. Bladder dysfunction in patients with cauda equina lesions. Neurourol Urodyn 2006;25:23–31.
47. Fowler CJ, Christmas TJ, Chapple CR, et al. Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome? BMJ 1988;297:1436–8.
48. Podnar S. Nomenclature of the electrophysiologically tested sacral reflexes. Neurourol Urodyn 2006;25:95–7.
49. Lefaucheur JP, Labat JJ, Amarenco G, et al. What is the place of electroneuromyographic studies in the diagnosis and management of pudendal neuralgia related to entrapment syndrome? Neurophysiol Clin 2007;37:223–8.
50. Opsomer RJ, Guerit JM, Wese FX, Van Cangh PJ. Pudendal cortical somatosensory evoked potentials. J Urol 1986;135:1216–8.
51. Cavalcanti GA, Bruschini H, Manzano GM, et al. Pudendal somatosensory evoked potentials in normal women. Int Braz J Urol 2007;33:815–21.
52. Delodovici ML, Fowler CJ. Clinical value of the pudendal somatosensory evoked potential. Electroencephalogr Clin Neurophysiol 1995;96:509–15.
53. Panicker JN, Menon L, Anandkumar A, Sundaram KR, Fowler CJ. Lower urinary tract symptoms following neurological illness may be influenced by multiple factors: observations from a neurorehabilitation service in a developing country. Neurourol Urodyn 2010;29:378–81.
54. Panicker J, de Sèze M, Fowler C. Neurogenic lower urinary tract dysfunction and its management. Clin Rehab. In press.

References

1. Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int 2008;102:62–6.
2. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002;11:560–5.
3. Wallace SA, Roe B, Williams K, Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2004(1):CD001308.
4. Ostaszkiewicz J, Roe B, Johnston L. Effects of timed voiding for the management of urinary incontinence in adults: systematic review. J Adv Nurs 2005;52:420–31.
5. Lennon S, Stokes M. Pocketbook of neurological physiotherapy. Edinburgh: Churchill Livingstone; 2008.
6. Laycock J, Whelan M, Dumoulin C. Patient assessment. In: Haslam J, Laycock J, eds. Therapeutic management of incontinence and pelvic pain. London: Springer-Verlag; 2008:57–66.
7. Laycock J, Jerwood D. Pelvic floor assessment; the PERFECT scheme. Physiotherapy 2001;87:632–42.
8. Messelink B, Benson T, Berghmans B, et al. Standardization of terminology of pelvic floor muscle function and dysfunction: report from the pelvic floor clinical assessment group of the International Continence Society. Neurourol Urodyn 2005;24:374–80.
9. Miller JM, Ashton-Miller JA, DeLancey JO. A pelvic muscle precontraction can reduce cough-related urine loss in selected women with mild SUI. J Am Geriatr Soc 1998;46:870–4.
10. Dorey G. The male patient. In: Haslam J, Laycock J, eds. Therapeutic management of incontinence and pelvic pain. Second edn. London: Springer-Verlag; 2008:159–62.
11. Bo K. Pelvic floor muscle training is effective in treatment of female stress urinary incontinence, but how does it work? Int Urogynecol J Pelvic Floor Dysfunct 2004;15:76–84.
12. De Ridder D, Vermeulen C, Ketelaer P, Van Poppel H, Baert L. Pelvic floor rehabilitation in multiple sclerosis. Acta Neurol Belg 1999;99:61–4.
13. McClurg D, Lowe-Strong A, Ashe R. Pelvic floor training for lower urinary tract dysfunction in MS. Nurs Times 2009;105:45–7.
14. Mahony DT, Laferte RO, Blais DJ. Integral storage and voiding reflexes. Neurophysiologic concept of continence and micturition. Urology 1977;9:95–106.
15. Shafik A, Shafik IA. Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol 2003;20:374–7.
16. McClurg D, Ashe RG, Lowe-Strong AS. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis – a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn 2008;27:231–7.
17. Bo K, Herbert R. When and how should new therapies become routine clinical practice? . Physiotherapy 2009;95:51–7.
18. Kabay SC, Yucel M, Kabay S. Acute effect of posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with multiple sclerosis: urodynamic study. Urology 2008;71:641–5.
19. Kabay S, Kabay SC, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourol Urodyn 2009;28:62–7.
20. Fader M, Craggs M. Continence problems and neurological disability. In: Getliffe K, Dolman M, eds. Promoting continence: a clinical and research resource. London:Baillière Tindall (Elsevier Science); 2003:337–70.
21. Abrams P, Agarwal M, Drake M, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int 2008;101:989–94.
22. Dasgupta P, Haslam C, Goodwin R, Fowler C. The Queen Square bladder stimulator: a device for assisting emptying of the neurogenic bladder. Br J Urol 1997;80:234–7.
23. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003;17:42–7.
24.. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:470–7.
25. Royal College of Nursing. Catheter Care. RCN Guidance for Nurses. London: Royal College of Nursing; 2008.
26. Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol 1972;107:458–61.
27. Getliffe K, Fader M. Catheters and containment products. In: Getliffe K, Dolman M, eds. Promoting continence: a clinical and research resource. London:Baillière Tindall (Elsevier Science); 2007:159–308.
28. Logan K. Designing a catheter skills training programme. Nurs Times 2008;104:42–3.
29. Scottish Intercollegiate Guidelines Network. Management of urinary incontinence in primary care – a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2008.
30. Pomfret I. Urinary catheterization: selection and clinical management. Br J Community Nurs 2007;12:348–54.
31. Pomfret I. Catheter care – trouble shooting. Journal of Community Nursing 1991;13:20–4.
32. MacDiarmid SA, Arnold EP, Palmer NB, Anthony A. Management of spinal cord injured patients by indwelling suprapubic catheterization. J Urol 1995;154(2 Pt 1):492–4.
33. Ebner A, Madersbacher H, Schober F, et al. Hydrodynamic properties of Foley catheters and its clinical relevance. Proceedings of the International Continence Society 15th Meeting. London: 1985.
34. Disability Equipment Assessment. Catheter valves – a multi-centre comparative evaluation. London: Medical Device Agency; 1997.
35. Dasgupta P, Haslam C. Treatment of neurogenic bladder dysfunction. In: Fowler C, ed. Neurology of bladder, bowel and sexual dysfunction. Boston: Butterworth Heinemann; 1999:163–83.
36. Paterson J. Stigma associated with post-prostatectomy urinary incontinence. Journal of Wound, Ostomy and Continence Nursing 2000;27:168–73.

References

1. De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006;25:156–61.
2. Iijima K, De Wachter S, Wyndaele JJ. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 2007;52:842–7.
3. Yokoyama O, Yusup A, Miwa Y, et al. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol 2005;174:2032–6.
4. Boy S, Schurch B, Mehnert U, et al. The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results. BJU Int 2007;100:574–8.
5. Matsui M, Motomura D, Karasawa H, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci USA 2000;97:9579–84.
6. Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004;309:1148–53.
7. Takahashi R, Nishimura J, Hirano K, et al. Ca2+ sensitization in contraction of human bladder smooth muscle. J Urol 2004;172:748–52.
8. Ehlert FJ, Griffin MT, Abe DM, et al. The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther 2005;313:368–78.
9. Pontari MA, Braverman AS, Ruggieri MR, Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004;286:R874–80.
10. Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 2007;4:46–54.
11. Mukerji G, Yiangou Y, Grogono J, et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006;176:367–73.
12. Yoshida M, Masunaga K, Satoji Y, et al. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance. J Pharmacol Sci 2008;106:193–8.
13. Yoshida M, Inadome A, Maeda Y, et al. Non-neuronal cholinergic system in human bladder urothelium. Urology 2006;67:425–30.
14. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380–94.
15. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population. Int J Urol 2008;15:778–88.
16. Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006;98:503–7.
17. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5–26.
18. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003;326:841–4.
19. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543–62.
20. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740–63.
21. Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995–2000.
22. Wyndaele JJC, Kovindha A, Madersbacher H, et al. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Paris: Health Publication Ltd; 2009:793–960.
23. Mori S, Kojima M, Sakai Y, Nakajima K. Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride. Nippon Ronen Igakkai Zasshi 1999;36:489–94.
24. Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 2009:CD004193.
25. Amend B, Hennenlotter J, Schafer T, et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53:1021–8.
26. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006;25:441–5.
27. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46–53.
28. Pak RW, Petrou SP, Staskin DR. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003;4:436–40.
29. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636–44.
30. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003;42:1243–85.
31. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008;62:1792–800.
32. Kay GG, Abou-Donia MB, Messer WS, Jr., et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005;53:2195–201.
33. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005;27:127–38.
34. Bowman GL, Kaye JA, Moore M, et al. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 2007;68:1809–14.
35. Pakulski C, Drobnik L, Millo B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit 2000;6:314–18.
36. Starr JM, Wardlaw J, Ferguson K, et al. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003;74:70–6.
37. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565–78.
38. Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 2004;145:59–66.
39. Tzavara ET, Bymaster FP, Felder CC, et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 2003;8:673–9.
40. Seeger T, Fedorova I, Zheng F, et al. M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 2004;24:10117–27.
41. Yamada M, Miyakawa T, Duttaroy A, et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001;410:207–12.
42. Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6:51–8.
43. Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease – the pivotal role of brain M1 receptors. Neurodegener Dis 2008;5:237–40.
44. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465–73.
45. Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007;30:54–8.
46. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50:317–26.
47. Giramonti KM, Kogan BA, Halpern LF. The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn 2008;27:315–18.
48. Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8–13.
49. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry 2010;81:160–5.
50. Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG. Cognitive impairments and depression in Parkinson's disease: a follow up study. J Neurol Neurosurg Psychiatry 1990;53:597–602.
51. Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81–8.
52. Eckford SD, Swami KS, Jackson SR, Abrams PH. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol 1994;74:733–5.
53. Hilton P, Hertogs K, Stanton SL. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983;46:854–5.
54. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996;53:1270–5.
55. Zahariou A, Karagiannis G, Papaioannou P, Stathi K, Michail X. The use of desmopressin in the management of nocturnal enuresis in patients with spinal cord injury. Eura Medicophys 2007;43:333–8.
56. Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006;25:105–9.
57. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976;48:255–63.
58. Schwinn DA. The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001;88(Suppl 2):27–34.
59. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948;153:586–600.
60. Langer SZ. Presynaptic regulation of catecholamine release. Biochem Pharmacol 1974;23:1793–800.
61. Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 2002;19:390–6.
62. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999;161:635–40.
63. Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993;150:546–51.
64. Malloy BJ, Price DT, Price RR, et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 1998;160:937–43.
65. Hampel C, Dolber PC, Smith MP, et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002;167:1513–21.
66. Schwinn DA, Price RR. Molecular pharmacology of human alpha1-adrenergic receptors: unique features of the alpha 1a-subtype. Eur Urol 1999;36(Suppl 1):7–10.
67. Noble AJ, Chess-Williams R, Couldwell C, et al. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol 1997;120:231–8.
68. Tatemichi S, Akiyama K, Kobayashi M, et al. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 2006;176:1236–41.
69. Trevisani M, Campi B, Gatti R, et al. The influence of alpha1-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract. Eur Urol 2007;52:901–8.
70. Yokoyama O, Yusup A, Oyama N, et al. Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats. J Urol 2007;177:771–5.
71. Robinson D, Cardozo L, Terpstra G, Bolodeoku J. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 2007;100:840–5.
72. Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993;45:253–308.
73. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88–119.
74. Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 2008;377:473–81.
75. Leon LA, Hoffman BE, Gardner SD, et al. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzo dioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther 2008;326:178–85.
76. Frazier EP, Peters SL, Braverman AS, Ruggieri MR, Sr., Michel MC. Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 2008;377:449–62.
77. Kaidoh K, Igawa Y, Takeda H, et al. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 2002;168:1247–52.
78. Drake MJ. Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opin Emerg Drugs 2008;13:431–46.
79. Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (blossom) shows novel β3 adrenoceptor agonist ym178 is effective and well tolerated in the treatment of symptoms of overactive bladder. European Urol Supplements 2008;7:239.
80. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84:935–86.
81. Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 2007;26:928–33.
82. Truss MC, Stief CG, Uckert S, et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 2001;19:344–50.
83. Kaiho Y, Nishiguchi J, Kwon DD, et al. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int 2008;101:615–20.
84. Gillespie JI. Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder. BJU Int 2004;93:1325–32.
85. Giembycz MA. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005;5:238–44.
86. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236–44.
87. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401–7.
88. Gratzke C, Streng T, Park A, et al. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol 2009;181:1939–48.
89. Hiragata S, Ogawa T, Hayashi Y, et al. Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 2007;70:202–8.
90. Tyagi V, Philips BJ, Su R, et al. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 2009;181:1932–8.
91. Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425–33.
92. Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17:636–41.
93. Kavia R, De Ridder D, Constantinescu S, Fowler CJ. Randomised controlled trial of sativex to treat detrusor over activity in multiple sclerosis. JNNP 2010;submitted.
94. Liu L, Mansfield KJ, Kristiana I, et al. The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. Neurourol Urodyn 2007;26:433–8.
95. Charrua A, Cruz CD, Narayanan S, et al. GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol 2009;181:379–86.
96. Mochizuki T, Sokabe T, Araki I, et al. The TRPV4 cation channel mediates stretch-evoked Ca2+ influx and ATP release in primary urothelial cell cultures. J Biol Chem 2009;284:21257–64.
97. Gevaert T, Vriens J, Segal A, et al. Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest 2007;117:3453–62.
98. de Groat WC, Kawatani M, Hisamitsu T, et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990;30(Suppl):S71–7.
99. Jancso N, Jancso-Gabor A, Szolcsanyi J. The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat. Br J Pharmacol Chemother 1968;33:32–41.
100. Fowler CJ, Jewkes D, McDonald WI, Lynn B, de Groat WC. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992;339:1239.
101. Montell C. Physiology, phylogeny, and functions of the TRP superfamily of cation channels. Sci STKE 2001;RE1.
102. Olah Z, Szabo T, Karai L, et al. Ligand-induced dynamic membrane changes and cell deletion conferred by vanilloid receptor 1. J Biol Chem 2001;276:11021–30.
103. Olah Z, Karai L, Iadarola MJ. Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1. J Biol Chem 2001;276:31163–70.
104. Caudle RM, Karai L, Mena N, et al. Resiniferatoxin-induced loss of plasma membrane in vanilloid receptor expressing cells. Neurotoxicology 2003;24:895–908.
105. Dasgupta P, Chandiramani VA, Beckett A, Scaravilli F, Fowler CJ. The effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyper-reflexia. BJU Int 2000;85:238–45.
106. Brady CM, Apostolidis AN, Harper M, et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004;93:770–6.
107. Avelino A, Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol 2006;373:287–99.
108. Dasgupta P, Fowler CJ, Stephen RL. Electromotive drug administration of lidocaine to anesthetize the bladder before intravesical capsaicin. J Urol 1998;159:1857–61.
109. Apostolidis A, Brady CM, Yiangou Y, et al. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology 2005;65:400–5.
110. Apostolidis A, Yiangou Y, Brady C, et al. Endothelial nitric oxide synthase (eNOS) expression in neurogenic urinary bladders treated with intravesical resiniferatoxin (RTX). BJU Int 2004;93:336–40.
111. de Seze M, Wiart L, Ferriere J, et al. Intravesical instillation of capsaicin in urology: a review of the literature. Eur Urol 1999;36:267–77.
112. Reitz A, Schurch B. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord 2004;42:267–72.
113. MacDonald R, Monga M, Fink HA, Wilt TJ. Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med 2008;31:157–65.
114. Silva C, Rio ME, Cruz F. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol 2000;38:444–52.
115. Kuo HC. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J Urol 2003;170:835–9.
116. Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 2002;167:1710–14.
117. Kim JH, Rivas DA, Shenot PJ, et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med 2003;26:358–63.
118. Dasgupta P, Chandiramani V, Parkinson MC, Beckett A, Fowler CJ. Treating the human bladder with capsaicin: is it safe? Eur Urol 1998;33:28–31.
119. Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004;172:240–3.
120. De Ridder D, Chandiramani V, Dasgupta P, et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. J Urol 1997;158:2087–92.
121. de Seze M, Wiart L, de Seze MP, et al. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 2004;171:251–5.
122. Lazzeri M, Beneforti P, Spinelli M, Zanollo A, Barbagli G, Turini D. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol 2000;164:676–9.
123. Lazzeri M, Spinelli M, Beneforti P, Zanollo A, Turini D. Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand J Urol Nephrol 1998;32:331–4.
124. Silva C, Avelino A, Souto-Moura C, Cruz F. A light- and electron-microscopic histopathological study of human bladder mucosa after intravesical resiniferatoxin application. BJU Int 2001;88:355–60.
125. Lecci A, Giuliani S, Meini S, Maggi CA. Nociceptin and the micturition reflex. Peptides 2000;21:1007–21.
126. Lazzeri M, Calo G, Spinelli M, et al. Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study. J Urol 2001;166:2237–40.
127. Lazzeri M, Calo G, Spinelli M, et al. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study. Urology 2003;61:946–50.
128. Onizuka S, Takasaki M, Syed NI. Long-term exposure to local but not inhalation anesthetics affects neurite regeneration and synapse formation between identified lymnaea neurons. Anesthesiology 2005;102:353–63.
129. Higson RH, Smith JC, Hills W. Intravesical lignocaine and detrusor instability. Br J Urol 1979;51:500–3.
130. Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 2005;65:45–8.
131. Lazzeri M, Calo G, Spinelli M, et al. Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study. J Urol 2006;176:2098–102.
132. Lapointe SP, Wang B, Kennedy WA, Shortliffe LM. The effects of intravesical lidocaine on bladder dynamics of children with myelomeningocele. J Urol 2001;165:2380–2.
133. Wyndaele JJ, Castro D, Madersbacher H, et al. Neurologic urinary and fecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Paris: Health Publications Ltd; 2004:1059–162.
134. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43(Suppl 1):S16–24.
135. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200–5.
136. Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist 2008;14:289–98.
137. Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int 2007;99:247–62.
138. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139:919–22.
139. Smith CP, Franks ME, McNeil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003;169:1896–900.
140. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644–50.
141. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977–82.
142. Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006;175:2341–4.
143. Datta SN, Popat R, Elneil S, et al. Cholinergic signalling pathways in the superficial layers of the human bladder: Comparing health, disease and the effect of botulinum toxin type A. J Urol 2009;181:676–7.
144. Roosen A, Datta SN, Chowdhury RA, et al. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol 2009;55:1440–9.
145. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004;45:987–93.
146. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245–58.
147. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125–33.
148. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004;172:1529–32.
149. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692–7.
150. Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003;92:325–6.
151. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European Consensus Report. Eur Urol 2009;51:100–19.
152. Karsenty G, Elzayat E, Delapparent T, et al. Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007;177:1011–14.
153. Mouttalib S, Castel-Lacanal E, Guillotreau J, et al. Une antibioprophylaxie est-elle necessaire lors de la realisation d'injections intradetrusoriennes de toxine botulique A dans le traitement d'une hyperactivite detrusorienne neurogene? Prog Urol 2009;19:667.
154. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452–7.
155. Molgo J, Lemeignan M, Thesleff S. Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve 1987;10:464–70.
156. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40:599–600.
157. Kalsi V, Apostolidis A, Gonzales G, et al. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 2008;54:181–7.
158. Rapp DE, Lucioni A, Katz EE, et al. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004;63:1071–5.
159. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510–15.
160. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196–200.
161. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007;41:335–40.
162. Popat R, Apostolidis A, Kalsi V, et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984–8.
163. Del Popolo G, Filocamo MT, Li Marzi V, et al. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 2008;53:1013–20.
164. Schulte-Baukloh H, Knispel HH, Stolze T, et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005;66:865–70.
165. Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009;55:705–11.
166. Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006;68:993–7.
167. Ruffion A, Capelle O, Paparel P, et al. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006;97:1030–4.
168. Del Popolo G. Botulinum-A toxin in the treatment of detrusor hyperreflexia. 31st Annual Meeting of the International Continence Society, Seoul, Korea, 2001: Abstract 2001.
169. Kessler TM, Danuser H, Schumacher M, Studer UE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005;24:231–6.
170. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004;63:868–72.
171. Schulte-Baukloh H, Schobert J, Stolze T, et al. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 2006;25:110–15.
172. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47:653–9.
173. Kalsi V, Popat RB, Apostolidis A, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49:519–27.
174. Khan S, Kessler TM, Panicker J, et al. Sustained and significant quality of life improvement after intra-detrusor botulinum toxin type A injections for neurogenic detrusor overactivity secondary to multiple sclerosis. Br J Urol 2009;103:37.
175. Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 2006;68:17–28.
176. Schurch B, Denys P, Kozma CM, et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007;52:850–8.
177. Game X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008;53:613–18.
178. Wefer B, Ehlken B, Bremer J, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany. World J Urol; DOI 10.1007/s00345-009-0466-1 (not yet published in journal).
179. Leyson JF, Martin BF, Sporer A. Baclofen in the treatment of detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1980;124:82–4.
180. Denys P, Mane M, Azouvi P, et al. Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. Arch Phys Med Rehabil 1998;79:494–6.
181. Murdock MM, Sax D, Krane RJ. Use of dantrolene sodium in external sphincter spasm. Urology 1976;8:133–7.
182. Abrams P, Amarenco G, Bakke A, et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003;170:1242–51.
183. Reitz A, Knapp PA, Muntener M, Schurch B. Oral nitric oxide donors: a new pharmacological approach to detrusor-sphincter dyssynergia in spinal cord injured patients? Eur Urol 2004;45:516–20.

References

1. Saxtorph M. Stricture urethrae, fistula perinee, retentio urinae. Clinisk Chirurgi Copenhagen Gyldenldalske Fortlag 1887:265–80.
2. Katona F, Benyo I, Lang I. Uber intraluminare Elektrotherapie von verschiedenen paralytischen Zustanden des Gastroinestinalen Traktes mit Quadrangularstrom. Zentralbl Chir 1959;84:929–33.
3. Ebner A, Jiang C, Lindstrom S. Intravesical electrical stimulation – an experimental analysis of the mechanism of action. J Urol 1992;148:920–4.
4. Gladh G, Mattsson S, Lindstrom S. Intravesical electrical stimulation in the treatment of micturition dysfunction in children. Neurourol Urodyn 2003;22:233–42.
5. Madersbacher H. Intravesical electrical stimulation for the rehabilitation of the neuropathic bladder. Paraplegia 1990;28:349–52.
6. Boone TB, Roehrborn CG, Hurt G. Transurethral intravesical electrotherapy for neurogenic bladder dysfunction in children with myelodysplasia: a prospective, randomized clinical trial. J Urol 1992;148(2 Pt 2):550–4.
7. Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 1988;140:1331–9.
8. Ruud Bosch JL, Groen J. Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. Lancet 1996;348:717–19.
9. Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology 2005;66:746–50.
10. Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, et al. Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 2000;164:1476–80.
11. Hohenfellner M, Humke J, Hampel C, et al. Chronic sacral neuromodulation for treatment of neurogenic bladder dysfunction: long-term results with unilateral implants. Urology 2001;58:887–92.
12. Scheepens WA, Jongen MM, Nieman FH, et al. Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction. Urology 2002;60:598–602.
13. Guys JM, Haddad M, Planche D, et al. Sacral neuromodulation for neurogenic bladder dysfunction in children. J Urol 2004;172(4 Pt 2):1673–6.
14. Lombardi G, Del Popolo G. Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms. Spinal Cord 2009;47:486–91.
15. Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007;197:96.e1–5.
16. Fowler CJ, Swinn MJ, Goodwin RJ, Oliver S, Craggs M. Studies of the latency of pelvic floor contraction during peripheral nerve evaluation show that the muscle response is reflexly mediated. J Urol 2000;163:881–3.
17. Schurch B, Reilly I, Reitz A, Curt A. Electrophysiological recordings during the peripheral nerve evaluation (PNE) test in complete spinal cord injury patients. World J Urol 2003;20:319–22.
18. Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol 2005;174:2268–72.
19. Spinelli M, Giardiello G, Arduini A, van den Hombergh U. New percutaneous technique of sacral nerve stimulation has high initial success rate: preliminary results. Eur Urol 2003;43:70–4.
20. Scheepens WA, Weil EH, van Koeveringe GA, et al. Buttock placement of the implantable pulse generator: a new implantation technique for sacral neuromodulation – a multicenter study. Eur Urol 2001;40:434–8.
21. van Voskuilen AC, Oerlemans DJ, Weil EH, de Bie RA, van Kerrebroeck PE. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol 2006;49:366–72.
22. Van Rey F, Jongen PJH, Heesakkers J. Treatment of voiding dysfunction by neuromodulation in a selected MS patient population. Eur Urol 2009;8:241.
23. Sievert KD, Amend B, Gakis G, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol 2010;67:74–84.
24. Bosch JL, Groen J. Sacral nerve neuromodulation in the treatment of patients with refractory motor urge incontinence: long-term results of a prospective longitudinal study. J Urol 2000;163:1219–22.
25. Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000;56(6 Suppl 1):87–91.
26. Everaert K, De Ridder D, Baert L, Oosterlinck W, Wyndaele JJ. Patient satisfaction and complications following sacral nerve stimulation for urinary retention, urge incontinence and perineal pain: a multicenter evaluation. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:231–5.
27. Grunewald V, Hofner K, Thon WF, Kuczyk MA, Jonas U. Sacral electrical neuromodulation as an alternative treatment option for lower urinary tract dysfunction. Restor Neurol Neurosci 1999;14:189–93.
28. Dasgupta R, Wiseman OJ, Kitchen N, Fowler CJ. Long-term results of sacral neuromodulation for women with urinary retention. BJU Int 2004;94:335–7.
29. Elhilali MM, Khaled SM, Kashiwabara T, Elzayat E, Corcos J. Sacral neuromodulation: long-term experience of one center. Urology 2005;65:1114–17.
30. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178:2029–34.
31. Brindley GS. An implant to empty the bladder or close the urethra. J Neurol Neurosurg Psychiatry 1977;40:358–69.
32. Brindley GS. The actions of parasympathetic and sympathetic nerves in human micturition, erection and seminal emission, and their restoration in paraplegic patients by implanted electrical stimulators. Proc R Soc Lond 1988;235:111–20.
33. Egon G, Chartier-Kastler E, Denys P, Ruffion A. Traumatise medullaire et neuro-stimulation de Brindley. Prog Urol 2007;1:535–9.
34. Brindley GS, Polkey CE, Rushton DN. Sacral anterior root stimulators for bladder control in paraplegia. Paraplegia 1982;20:365–81.
35. Barat M, Egon G, Daverat P, et al. L'electrostimulation des racines sacrees anterieures dans le traitement des neurovessies centrales. J Urol (Paris) 1993;99:3–7.
36. Brindley GS. The first 500 patients with sacral anterior root stimulator implants: general description. Paraplegia 1994;32:795–805.
37. Van Kerrebroeck PE, Koldewijn EL, Rosier PF, Wijkstra H, Debruyne FM. Results of the treatment of neurogenic bladder dysfunction in spinal cord injury by sacral posterior root rhizotomy and anterior sacral root stimulation. J Urol 1996;155:1378–81.
38. Schurch B, Rodic B, Jeanmonod D. Posterior sacral rhizotomy and intradural anterior sacral root stimulation for treatment of the spastic bladder in spinal cord injured patients. J Urol 1997;157:610–14.
39. Egon G, Barat M, Colombel P, et al. Implantation of anterior sacral root stimulators combined with posterior sacral rhizotomy in spinal injury patients. World J Urol 1998;16:342–9.
40. van der Aa HE, Alleman E, Nene A, Snoek G. Sacral anterior root stimulation for bladder control: clinical results. Arch Physiol Biochem 1999;107:248–56.
41. Creasey GH, Grill JH, Korsten M, et al. An implantable neuroprosthesis for restoring bladder and bowel control to patients with spinal cord injuries: a multicenter trial. Arch Phys Med Rehabil 2001;82:1512–19.
42. Bauchet L, Segnarbieux F, Martinazzo G, Frerebeau P, Ohanna F. Traitement neurochirurgical de la vessie hyperactive chez le blesse medullaire. Neurochirurgie 2001;47:13–24.
43. Vignes JR, Liguoro D, Sesay M, Barat M, Guerin J. Dorsal rhizotomy with anterior sacral root stimulation for neurogenic bladder. Stereotact Funct Neurosurg 2001;76:243–5.
44. Kutzenberger J, Domurath B, Sauerwein D. Spastic bladder and spinal cord injury: seventeen years of experience with sacral deafferentation and implantation of an anterior root stimulator. Artif Organs 2005;29:239–41.
45. Game X, Castel-Lacanal E, Bastie JP, et al. Évaluation de la charge en soins paramédicaux des patients neurologiques dans un service d'urologie. Prog Urol 2009;19:122–6.
46. Mahony DT, Laferte RO. Studis of enuresis. IV. Multiple detrusor myotomy: a new operation for the rehabilitation of severe detrusor hypertrophy and hypercontractility. J Urol 1972;107:1064–7.
47. Cartwright PC, Snow BW. Bladder autoaugmentation: early clinical experience. J Urol 1989;142(2 Pt 2):505–8.
48. Ehrlich RM, Gershman A. Laparoscopic seromyotomy (auto-augmentation) for non-neurogenic neurogenic bladder in a child: initial case report. Urology 1993;42:175–8.
49. Mammen T, Balaji KC. Robotic transperitoneal detrusor myotomy: description of a novel technique. J Endourol 2005;19:476–9.
50. Kumar SP, Abrams PH. Detrusor myectomy: long-term results with a minimum follow-up of 2 years. BJU Int 2005;96:341–4.
51. MacNeily AE, Afshar K, Coleman GU, Johnson HW. Autoaugmentation by detrusor myotomy: its lack of effectiveness in the management of congenital neuropathic bladder. J Urol 2003;170(4 Pt 2):1643–6.
52. Potter JM, Duffy PG, Gordon EM, Malone PR. Detrusor myotomy: a 5-year review in unstable and non-compliant bladders. BJU Int 2002;89:932–5.
53. Marte A, Di Meglio D, Cotrufo AM, et al. A long-term follow-up of autoaugmentation in myelodysplastic children. BJU Int 2002;89:928–31.
54. Leng WW, Blalock HJ, Fredriksson WH, English SF, McGuire EJ. Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation. J Urol 1999;161:758–63.
55. Von Mikulicz J. Zur operation der angerborenen blasensplate. Zentralbl Chir 1889;26:641–3.
56. Rink RC. Bladder augmentation. Options, outcomes, future. Urol Clin North Am 1999;26:111–23.
57. Liard A, Seguier-Lipszyc E, Mathiot A, Mitrofanoff P. The Mitrofanoff procedure: 20 years later. J Urol 2001;165(6 Pt 2):2394–8.
58. Monti PR, de Carvalho JR. Tubulisation transversale de segments intestinaux: un conduit catheterisable alternatif au procede de Mitrofanoff. Prog Urol 2001;11:382–4.
59. Game X, Karsenty G, Chartier-Kastler E, Ruffion A. Traitement de l'hyperactivite detrusorienne neurologique: enterocystoplasties. Prog Urol 2007;17:584–96.
60. Chartier-Kastler EJ, Mongiat-Artus P, Bitker MO, et al. Long-term results of augmentation cystoplasty in spinal cord injury patients. Spinal Cord 2000;38:490–4.
61. Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJU Int 2001;88:511–25.
62. Khoury AE, Salomon M, Doche R, et al. Stone formation after augmentation cystoplasty: the role of intestinal mucus. J Urol 1997;158(3 Pt 2):1133–7.
63. Nurse DE, McInerney PD, Thomas PJ, Mundy AR. Stones in enterocystoplasties. Br J Urol 1996;77:684–7.
64. Shaw J, Lewis MA. Bladder augmentation surgery – what about the malignant risk? Eur J Pediatr Surg 1999;9(Suppl 1):39–40.
65. Shekarriz B, Upadhyay J, Demirbilek S, Barthold JS, Gonzalez R. Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. Urology 2000;55:123–8.
66. Khastgir J, Hamid R, Arya M, Shah N, Shah PJ. Surgical and patient reported outcomes of “clam” augmentation ileocystoplasty in spinal cord injured patients. Eur Urol 2003;43:263–9.
67. Mundy AR, Stephenson TP. “Clam” ileocystoplasty for the treatment of refractory urge incontinence. Br J Urol 1985;57:641–6.
68. Caione P, Capozza N, Zavaglia D, Palombaro G, Boldrini R. In vivo bladder regeneration using small intestinal submucosa: experimental study. Pediatr Surg Int 2006;22:593–9.
69. Barrington JW, Dyer R, Bano F. Bladder augmentation using Pelvicol implant for intractable overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:50–3.
70. Atala A. Tissue engineering of artificial organs. J Endourol 2000;14:49–57.
71. Mitrofanoff P. Cystostomie continente transappendiculaire dans le traitement des vessies neurologiques. Chir Pediatr 1980;21:297–305.
72. Lemelle JL, Simo AK, Schmitt M. Comparative study of the Yang-Monti channel and appendix for continent diversion in the Mitrofanoff and Malone principles. J Urol 2004;172(5 Pt 1):1907–10.
73. Karsenty G, Chartier-Kastler E, Mozer P, et al. A novel technique to achieve cutaneous continent urinary diversion in spinal cord-injured patients unable to catheterize through native urethra. Spinal Cord 2008;46:305–10.
74. Salom EM, Mendez LE, Schey D, et al. Continent ileocolonic urinary reservoir (Miami pouch): the University of Miami experience over 15 years. Am J Obstet Gynecol 2004;190:994–1003.
75. Karsenty G, Vidal F, Ruffion A, Chartier-Kastler E. Derivation cutanee continente en neuro-urologie. Prog Urol 2007;17:542–51.
76. Moreno JG, Chancellor MB, Karasick S, et al. Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. Arch Phys Med Rehabil 1995;76:758–62.
77. Game X, Mallet R, Guillotreau J, et al. Uterus, fallopian tube, ovary and vagina-sparing laparoscopic cystectomy: technical description and results. Eur Urol 2007;51:441–6.
78. Chartier-Kastler EJ, Mozer P, Denys P, et al. Neurogenic bladder management and cutaneous non-continent ileal conduit. Spinal Cord 2002;40:443–8.
79. Hubert J, Chammas M, Larre S, et al. Initial experience with successful totally robotic laparoscopic cystoprostatectomy and ileal conduit construction in tetraplegic patients: report of two cases. J Endourol 2006;20:139–43.
80. Guillotreau J, Game X, Castel-Lacanal E, et al. Cystectomie laparoscopique et ureterostomie trans-ileale pour troubles vesico-sphincteriens d'origine neurologique. Evaluation de la morbidite. Prog Urol 2007;17:208–12.
81. Bart S, Game X, Mozer P, Ruffion A, Chartier-Kastler E. Derivation cutanee non continente en neuro-urologie. Prog Urol 2007;17:552–8.
82. McDougal WS. Use of intestinal segments and urinary diversion. In: Walsh PC, Retik AB, Kavoussi LR, et al, eds. Campbell's urology. Philadelphia: WB Saunders; 2002.
83. Herschorn S, Rangaswamy S, Radomski SB. Urinary undiversion in adults with myelodysplasia: long-term followup. J Urol 1994;152(2 Pt 1):329–33.
84. Fontaine E, Hajri M, Rhein F, et al. Reappraisal of endoscopic sphincterotomy for post-traumatic neurogenic bladder: a prospective study. J Urol 1996;155:277–80.
85. Chartier-Kastler E, Mozer P, Ayoub N, Richard F, Ruffion A. Hypertrophie benigne de la prostate et neuro-urologie. Prog Urol 2007;17:529–34.
86. Game X, Chartier-Kastler E, Ayoub N, et al. Outcome after treatment of detrusor-sphincter dyssynergia by temporary stent. Spinal Cord 2008;46:74–7.
87. Low AI, McRae PJ. Use of the Memokath for detrusor-sphincter dyssynergia after spinal cord injury – a cautionary tale. Spinal Cord 1998;36:39–44.
88. Denys P, Thiry-Escudie I, Ayoub N, et al. Urethral stent for the treatment of detrusor-sphincter dyssynergia: evaluation of the clinical, urodynamic, endoscopic and radiological efficacy after more than 1 year. J Urol 2004;172:605–7.
89. Rivas DA, Chancellor MB, Bagley D. Prospective comparison of external sphincter prosthesis placement and external sphincterotomy in men with spinal cord injury. J Endourol 1994;8:89–93.
90. Chancellor MB, Gajewski J, Ackman CF, et al. Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia. J Urol 1999;161:1545–50.
91. Hamid R, Khastgir J, Arya M, Patel HR, Shah PJ. Experience of tension-free vaginal tape for the treatment of stress incontinence in females with neuropathic bladders. Spinal Cord 2003;41:118–21.
92. Perez LM, Smith EA, Broecker BH, et al. Outcome of sling cystourethropexy in the pediatric population: a critical review. J Urol 1996;156(2 Pt 2):642–6.
93. Bastien L, Bart S, Vidart A, et al. Traitement de l'incontinence urinaire par insuffisance sphinctérienne neurologique à l'aide des ballons ACT™ (femme) et Pro-ACT™ (homme): résultats à 2 ans. Prog Urol 2008;18(Suppl 6):O87.
94. Ruffion A, Genevois S, Game X, et al. Peri-prostatic artificial urinary sphincter AMS 800 in adult neurogenic patients: a multi-centric study. Eur Urol 2009;8:244.
95. Game X, Bram R, Abu Anz S, et al. Laparoscopic insertion of artificial periprostatic urinary sphincter. Urology 2009;73:442 e1–3.

References

1. Glickmann S, Kamm MA. Bowel dysfunction in spinal-cord-injury patients. Lancet 1996;347:1651–3.
2. Krogh K, Nielsen J, Djurhuus JC, et al. Colorectal function in patients with spinal cord lesions. Dis Colon Rectum 1997;40:1233–9.
3. Stone JM, Nino-Murcia M, Wolfe VA, Perkash I. Chronic gastrointestinal problems in spinal cord injury patients: a prospective analysis. Am J Gastroenterol 1990;85:1114–19.
4. Lynch AC, Wong C, Anthony A, Dobbs BR, Frizelle FA. Bowel dysfunction following spinal cord injury: a description of bowel function in a spinal cord-injured population and comparison with age and gender matched controls. Spinal Cord 2000;38:717–23.
5. Menter R, Weitzenkamp D, Cooper D, et al. Bowel management outcomes in individuals with long-term spinal cord injuries. Spinal Cord 1997;35:608–612.
6. Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology 1990;98:1538–42.
7. Chia YW, Fowler CJ, Kamm MA, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol 1995;242:105–8.
8. Lie HR, Lagergren J, Rasmussen F, et al. Bowel and bladder control of children with myelomeningocele: a Nordic study. Dev Med Child Neurol 1991;33:1053–61.
9. Krogh K, Lie HR, Bilenberg N, Laurberg S. Bowel function in Danish children with myelomeningocele. APMIS 2003(Suppl 109):81–85.
10. Su Y, Zhang X, Zeng J, et al. New-onset constipation at acute stage after first stroke: incidence, risk factors and impact on stroke outcome. Stroke 2009;4:1304–9.
11. Bracci F, Badiali D, Pezzotti P, et al. Chronic constipation in hemiplegic patients. World J Gastroenterol 2007;13:3967–72.
12. Edwards LL, Quigley EMM, Pfeier RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992;42:726–32.
13. Krogh K, Ostergaard K, Sabroe S, Laurberg S. Clinical aspects of bowel symptoms in Parkinson's disease. Acta Neurol Scand 2008;117:60–4.
14. Faaborg PM, Christensen P, Finnerup N, Laurberg S, Krogh K. The pattern of colorectal dysfunction changes with time since spinal cord injury. Spinal Cord 2008;46:234–8.
15. Finnerup NB, Faaborg PM, Krogh K, Jensen TS. Abdominal pain in long-term spinal cord injury. Spinal Cord 2008;46:198–203.
16. Wiesel PH, Norton C, Brazzelli M. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev 2001;4:CD002115.
17. Alexander MS, Biering-Sorensen F, Bodner Det al. International standards to document remaining autonomic function after spinal cord injury. Spinal Cord 2009;47:36–43.
18. Krogh K, Christensen P, Sabroe S, Laurberg S. Neurogenic bowel dysfunction score. Spinal Cord 2006;44:625–631.
19. Krogh K, Perkash I, Stiens S, Biering-Sorensen F. International bowel function basic spinal cord injury data set. Spinal Cord 2009;47:230–4.
20. Krogh K, Perkash I, Stiens S, Biering-Sorensen F. International bowel function extended spinal cord injury data set. Spinal Cord 2009;47:235–41.
21. Alexander MS, Anderson KD, Biering-Sorensen Fet al. Outcome measures in spinal cord injury: recent assessments and recommendations for future directions. Spinal Cord 2009;47:582–91.
22. Leduc BE, Spacek E, Lepage Y. Colonic transit after spinal cord injury: any clinical significance? J Spinal Cord Med 2002;25:161–6.
23. Media S, Christensen P, Lauge I, et al. Reprodicibility and validity of radiographically determined gastrointestinal and segmental colonic transit times in spinal cord-injured patients. Spinal Cord 2009;47:72–5.
24. Christensen P, Bazzocchi G, Coggrave M, et al. Outcome of transanal irrigation for bowel dysfunction in patients with spinal cord injury. J Spinal Cord Med 2008;31:560–7.
25. Faaborg PM, Christensen P, Kvitsau B, et al. Long-term outcome and safety of transanal irrigation for neurogenic bowel dysfunction. Spinal Cord 2009;47:545–9.
26. Marino R, Barros T, Biering-Sorensen F, et al. International standards for neurological classification of spinal cord injury. J Spinal Cord Med 2003; 26(Suppl 1):S50–6.
27. Jorge JMN, Wexner SD. Etiology and management of faecal incontinence. Dis Colon Rectum 1993;36:77–97.
28. Vaizey CJ, Carapeti E, Cahill CA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut 1999;44:77–80.
29. Agachan F, Chen T, Pfeiffer J, Reisman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum 1996;39:681–5.
30. Christensen P, Bazzocchi G, Coggrave M, et al. A randomized controlled trial of transanal irrigation versus conservative bowel management in spinal cord-injured patients. Gastroenterology 2006;131:738–47.
31. DeVivo M, Biering-Sorensen F, Charlifue S, et al. International spinal cord injury core data set. Spinal Cord 2006;44:535–40.
32. Menardo G, Bausano G, Corazziari E, et al. Large-bowel transit in paraplegic patients. Dis Colon Rectum 1987;30:924–8.
33. Nino-Murcia M, Stone J, Chang P, Perkash I. Colonic transit in spinal cord-injured patients. Invest Radiol 1990;25:109–12.
34. Krogh K, Mosdal C, Laurberg S. Gastrointestinal and segmental transit times in patients with acute and chronic spinal cord injury. Spinal Cord 2000;38:615–21.
35. Krogh K, Bach Jensen M, Gandrup P, et al. Efficacy and tolerability of Prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterology 2002;37:431–6.
36. Keshavavarzian A, Barnes WE, Bruninga K, et al. Delayed colonic transit in spinal cord-injured patients measured by Indium 111 Amberlite scintigraphy. Am J Gastroenterol 1995;90:1295–300.
37. Freedman PN, Goldberg PA, Fataar AB, Mann MM. Comparison of methods of assessment of scintigraphic colonic transit. J Nuc Med Tech 2006;34:76–81.
38. Krogh K, Olsen N, Christensen P, Madsen JL, Laurberg S. Colorectal transport during defecation in patients with lesions of the sacral spinal cord. Neurogastroenterol Motil 2003;15:25–31.

References

1. Coggrave M, Norton C, Wilson-Barnett J. Management of neurogenic bowel dysfunction in the community after spinal cord injury: a postal survey in the United Kingdom. Spinal Cord 2009;47:323–30.
2. Bakke A, Myhr KM, Gronning M, Nyland H. Bladder, bowel and sexual dysfunction in patients with multiple sclerosis-a cohort study. Scand J Urol Nephrol Suppl 1996;179:61–6.
3. Chia YW, Fowler CJ, Kamm MA, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol 1995;242:105–8.
4. Hennessey A, Robertson NP, Swingler R, Compston DA. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 1999; 246:1027–32.
5. Ponticelli A, Iacobelli BD, Silveri M, et al. Colorectal dysfunction and faecal incontinence in children with spina bifida. Br J Urol 1998;81(Suppl 3):117–9.
6. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992;42:726–32.
7. Harari D, Coshall C, Rudd AG, Wolfe CD. New-onset fecal incontinence after stroke: prevalence, natural history, risk factors, and impact. Stroke 2003;34:144–50.
8. Del Giudice E, Staiano A, Capano G, et al. Gastrointestinal manifestations in children with cerebral palsy. Brain Dev 1999; 21: 307–11.
9. Brittain KR, Peet SM, Castleden CM. Stroke and incontinence. Stroke 1998;29:524–8.
10. McDonnell GV, McCann JP. Issues of medical management in adults with spinal bifida. Childs Nervous System 2000;16:222–27.
11. Nakayama H, Jorgensen HS, Pedersen PM, Raaschou HO, Olsen TS. Prevalence and risk factors of incontinence after stroke: The Copenhagen Stroke Study. Stroke 1997;28:58–62.
12. Correa GI, Rotter KP. Clinical evaluation and management of neurogenic bowel after spinal cord injury. Spinal Cord 2000;38:301–8.
13. De Looze DA, Van Laere M, De Muynck MC, Beke R, Elewaut A. Constipation and other chronic gastrointestinal problems in spinal cord injury patients. Spinal Cord 1998;36:63–6.
14. Han RR, Kim JH, Kwon BS. Chronic gastrointestinal problems and bowel dysfunction in patients with spinal cord injury. Spinal Cord 1998;36:485–90.
15. Harari D, Sarkarati M, Gurwitz J, McGlinchey-Berroth G, Minaker K. Constipation-related symptoms and bowel program concerning individuals with spinal cord injury. Spinal Cord 1997;35:394–401.
16. Lynch AC, Antony A, Dobbs BR, Frizelle FA. Bowel dysfunction following spinal cord injury. Spinal Cord 2001;39:193–203.
17. Menter R, Weitzenkamp D, Cooper D, et al. Bowel management outcomes in individuals with long-term spinal cord injuries. Spinal Cord 1997;35:608–12.
18. Stone JM, Wolfe VA, Nino-Murcia M, Perkash I. Colostomy as treatment for complications of spinal cord injury. Arch Phys Med Rehabil 1990;71:514–18.
19. Showkathali R, Antionios T. Autonomic dysreflexia; a medical emergency. J R Soc Med 2007;100:382–3.
20. Kavchak-Keyes MA. Autonomic hyperreflexia. Rehabil Nurs 2000;25:31–5.
21. Colachis SC3rd. Autonomic hyperreflexia with spinal cord injury. J Am Paraplegia Soc 1992;15:171–86.
22. Yoshimura M, Maejima H, Sasaki H. Bowel dysfunction and and disturbance of physical condition after evacuation in patients with chronic cervical spinal cord injury. Journal of Physical Therapy Science 2001;13:145–8.
23. De Lisa J, Kirshblum SA. Review: frustrations and needs in clinical care of spinal cord injury patients. J Spinal Cord Med 1997;20:384–90.
24. Ng C, Prott G, Rutkowski S, et al. Gastrointestinal symptoms in spinal cord injury: relationships with level of injury and psychologic factors. Dis Colon Rectum 2005;48:1562–8.
25. Glickman S, Kamm M. Bowel dysfunction in spinal-cord-injury patients. Lancet 1996;347:1651–3.
26. Coggrave M, Ingram R, Gardner B, Norton C.The impact of a stoma for bowel management after spinal cord injury. International Continence Society 2009. http://www.icsoffice.org/aspnet_membership/membership/Abstracts/AuthorIndex.aspx?EventID=47
27. Rogers, M. Living with paraplegia. London: Faber and Faber; 1991.
28. Anderson KD. Targeting recovery: priorities of the spinal cord injured population. J Neurotrauma 2004;21:1371–83.
29. Liu CW, Huang CC, Yang YH, et al. Relationship between neurogenic bowel dysfunction and health-related quality of life in persons with spinal cord injury. J Rehabil Med 2009;41:35–40.
30. Westgren N, Levi R. Quality of life and traumatic spinal cord injury. Arch Phys Med Rehabil 1998;79:1433–9.
31. Byrne CM, Pager CK, Rex J, Roberts R, Solomon MJ. Assessment of quality of life in the treatment of patients with neuropathic faecal incontinence. Dis Colon Rectum 1998;45:1431–6.
32. Stiens S, Bergman S, Goetz LL. Neurogenic bowel dysfunction after spinal cord injury: clinical evaluation and rehabilitative management. Arch Phys Med Rehabil 1997;78:S86–102.
33. Multidisciplinary Association of Spinal Cord Injury Professionals. Guidelines for managing neurogenic bowel dysfunction after spinal cord injury 2009. http://www.mascip.co.uk/pdfs/SIA-MASCIP_bowel_guidelines(1).pdf
34. Harari D, Norton C, Lockwood L, Swift C. Treatment of constipation and faecal incontinence in stroke patients: a randomised controlled trial. Stroke 2004;35:2549–55.
35. Krogh K, Christensen P, Sabroe S, Laurbeg S. Neurogenic bowel dysfunction score. Spinal Cord 2005;44:625–31.
36. Heaton, KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992;33:818–24.
37. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920–4.
38. Coggrave M. Neurogenic bowel management in chronic spinal cord injury: evidence for nursing care. King's College, London: unpublished PhD thesis, 2007.
39. Addison R, Smith M. Digital rectal examination (DRE) – manual evacuation of faeces guidelines on the role of the nurse. London: Royal College of Nursing UK; 1999.
40. Azpiroz F, Enck P, Whitehead E. Anorectal function testing: review of collective experience. Am J Gastroenterol 2002;97:232–40.
41. Kirk PM, King RB, Temple R, Bourjaily J, Thomas P. Long-term follow-up of bowel management after spinal cord injury. SCI Nursing 1997;14:56–63.
42. Creason N, Sparks D. Faecal impaction: a review. Nursing Diagnosis 2000;11:15–23.
43. Harari D. Bowel care in old age. In: Norton C, Chelvanayagam S, eds. Bowel continence nursing. Beaconsfield, UK: Beaconsfield Publishers; 2004:132–49.
44. Furasawa K, Sugiyama H, Tokuhiro A, et al. Topical anesthesia blunts the pressor response induced by bowel manipulation in subjects with cervical spinal cord injury. Spinal Cord 2008;47:144–8.
45. Cosman B, Vu T. Lidocaine anal block limits autonomic dysreflexia during anorectal procedures in spinal cord injury: a randomized, double-blind, placebo-controlled trial. Dis Colon Rectum 2005;48:1556–61.
46. Chen C; Su M; Tung S; Chang F; Wong J; Geraint M. Evaluation of polyethylene glycol plus electrolytes in the treatment of severe constipation and faecal impaction in adults. Current Medical Research Opinion 2005;21:1595–602.
47. Coggrave M, Wiesel PH, Norton C.Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev 2006;(2):CD002115.
48. Kirshblum S, Gulati M, O'Connor K, Voorman S. Bowel care practices in chronic spinal cord injury patients. Arch Phys Med Rehabil 1998;79:20–3.
49. Department of Health. Five a day – increasing fruit and vegetable consumption – a national priority. London: Department of Health; 2003. http://www.doh.gov.uk/fiveaday/
50. British Dietetic Association. Hydration. British Dietetic Association; 2006. http://www.bda.uk.com/hot_topics_hydration.html
51. Norton C, Whitehead WE, Bliss DZ, Harari D, Lang J. Conservative and pharmacological management of faecal incontinence in adults. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Plymouth: Health Publications; 2009.
52. Aaronson MJ, Freed MM, Burakoff R. Colonic myoelectric activity in persons with spinal cord injury. Dig Dis Sci 1985;30:295–300.
53. Glick M, Meshkinpour H, Haldeman S, et al. Colonic dysfunction in patients with thoracic spinal cord injury. Gastroenterology 1984;86:287–94.
54. Menardo G, Bausano G, Corazziari E, et al. Large-bowel transit in paraplegic patients. Dis Colon Rectum 1987;30:294–8.
55. Walter SA, Morren GL, Ryn AK, Hallbook O. Rectal pressure responses to a meal in patients with high spinal cord injury. Arch Phys Med Rehabil 2003;84:108–11.
56. Albers B, Cramer H, Fischer A, et al. Abdominal massage as intervention for patients with paraplegia caused by spinal cord injury – a pilot study. Pflege Z 2006;59:2–8.
57. Emly M, Cooper S, Vail A. Colonic motility in profoundly disabled people: a comparison of massage and laxative therapy in the management of constipation. Physiotherapy 1998;84:178–83.
58. Klauser AG, Flaschentrager J, Gehrke A, Muller-Lissner SA. Abdominal wall massage: effect on colonic function in healthy volunteers and in patients with chronic constipation. Z Gastroenterol 1992;30:247–51.
59. Coggrave M, Norton C, Wilson-Barnett J. Assessing interventions for bowel management using anorectal manometry. International Continence Society; 2006. http://www.icsoffice.org/publications/2007/pdf/0031.pdf
60. Consortium for spinal cord medicine. Neurogenic bowel management in adults with spinal cord injury. Clinical practice guidelines. Spinal Cord Medicine 1998;21:248.
61. Fajardo NR, Pasiliao RV, Modeste-Duncan R, et al. Decreased colonic motility in persons with chronic spinal cord injury. Am J Gastroenterol 2003;98:128–34.
62. Wiesel P, Bell S. Bowel dysfunction: assessment and management in the neurological patient. In: Norton C, Chelvanayagam S, eds. Bowel continence nursing. Beaconsfield, UK: Beaconsfield Publishers; 2004:181–203.
63. Kyle G, Oliver H, Prynn P. The procedure for the digital removal of faeces. Norgine Ltd; 2005.
64. Haas U, Geng V, Evers G, Knecht H. Bowel management in patients with spinal cord injury – a multicentre study of the German speaking society of paraplegia. Spinal Cord 2005;43:724–30.
65. Grundy D, Swain I. ABC of spinal cord injury. Fourth edn. BMJ Books; 2002.
66. Frisbie JH. Improved bowel care with a polyethylene glycol based bisacodyl suppository. J Spinal Cord Med 1997;20:227–9.
67. House J, Stiens S. Pharmacologically initiated defecation for persons with spinal cord injury: effectiveness of three agents. Arch Phys Med Rehabil 1997;78:1062–5.
68. Paran H, Butnaru G, Neufeld D, Magen A, Freund U. Enema-induced perforation of the rectum in chronically constipated patients. Dis Colon Rectum 1999;42:1609–12.
69. Dunn K, Galka M. A comparison of the effectiveness of Therevac SBTMand Bisacodyl suppositories in SCI patients bowel program. Rehabil Nurs 1994;19:334–8.
70. Amir IM, Sharma RM, Bauman WAM, Korsten MAM. Bowel care for individuals with spinal cord injury: comparison of four approaches. J Spinal Cord Med 1998;21:21–4.
71. Ehrenpreis E, Chang D, Eichenwald E. Pharmacotherapy for fecal incontinence: a review. Dis Colon Rectum 2007;50:641–9.
72. Wiesel PH, Norton C, Roy AJ, et al. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;69:240–3.
73. Norton C, Hosker G, Brazzelli M. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev 2000;(2):CD002111.
74. Shandling B, Gilmour RF. The enema continence catheter in spina bifida: successful bowel management. J Pediatr Surg 1987;22:271–3.
75. Christensen P, Krogh K, Buntzen S, Payandeh F, Laurberg S. Long-term outcome and safety of transanal irrigation for constipation and fecal incontinence. Dis Colon Rectum 2009;52:286–92.
76. Christensen P, Bazzocchi G, Coggrave M, et al. Treatment of fecal incontinence and constipation in patients with spinal cord injury – a prospective, randomized, controlled, multicentre trial of transanal irrigation vs. conservative bowel management. Gastroenterology 2006;131:738–47.
77. Del Popolo G, Mosiello G, Pilati C, et al. Treatment of neurogenic bowel dysfunction using transanal irrigation: a multicenter Italian study. Spinal Cord 2008;46:517–22.
78. Christensen P, Andreasen J, Ehlers L. Cost-effectiveness of transanal irrigation versus conservative bowel management for spinal cord injury patients. Spinal Cord 2009;47:138–43.
79. Christensen P, Bazzocchi G, Coggrave M, et al. Outcome of transanal irrigation for bowel dysfunction in patients with spinal cord injury. J Spinal Cord Med 2008;31:560–7.
80. Biering-Sorensen F, Bing J, Berggreen P, Olesen G. Rectum perforation during transanal irrigation: a case story. Spinal Cord 2009;47:266–7.
82. Teichman JM, Barber DB, Rogenes VJ, Harris JM. Malone antegrade continence enemas for autonomic dysreflexia secondary to neurogenic bowel. J Spinal Cord Med 1998;21:245–7.
83. Teichman JM, Zabihi N, Kraus SR, Harris JM, Barber DB. Long-term results for Malone antegrade continence enema for adults with neurogenic bowel disease. Urology 2003;61:502–6.
84. Gerharz EW, Vik V, Webb G, et al. The value of the MACE (Malone antegrade colonic enema) procedure in adult patients. J Am Coll Surg 1997;185:544–7.
85. Christensen, P, Kvitzau B, Krogh K, Buntzen S, Laurberg S. Neurogenic colorectal dysfunction – use of new antegrade and retrograde colonic wash-out methods. Spinal Cord 2000;38:255–61.
86. Bruce RG, el-Galley RE, Wells J, Galloway NT. Antegrade continence enema for the treatment of fecal incontinence in adults: use of gastric tube for catheterizable access to the descending colon. J Urol 1999;161:1813–6
87. National Institute for Health and Clinical Excellence. Percutaneous endoscopic colostomy. London: National Institute for Health and Clinical Excellence; 2006. http://guidance.nice.org.uk/IPG161
88. Cowlam S, Watson C, Elltringham M, et al. Percutaneous endoscopic colostomy of the left side of the colon. Gastrointest Endosc 2007;65:1007–14.
89. Stone J, Wolfe V, Nino-Murcia M, Perkash I. Colostomy as treatment for the complications of spinal cord injury. Arch Phys Med Rehabil 1990;71:514–18.
90. Kelly SR, Shashidharan M, Borwell B, et al. The role of intestinal stoma in patients with spinal cord injury. Spinal Cord 1999;37:211–14.
91. Branagan G, Tromans A, Finnis D. Effect of stoma formation on bowel care and quality of life in patients with spinal cord injury. Spinal Cord 2003;41:680–3.
92. Chia YW, Lee TK, Kour NW, Tung KH, Tan ES. Microchip implants on the anterior sacral roots in patients with spinal trauma: does it improve bowel function? Dis Colon Rectum 1996;39:690–4.
93. Creasey G, Grill J, Korsten M, et al. An implantable neuroprosthesis for restoring bladder and bowel control to patients with spinal cord injuries: a multicenter trial. Arch Phys Med Rehabil 2001;82:1512–19.
94. Binnie NR, Smith AN, Creasey GH, Edmond P. Constipation associated with chronic spinal cord injury: the effect of pelvic parasympathetic stimulation by the Brindley stimulator. Paraplegia 1991;29:463–9.
95. Valles M, Rodriguez A, Borau A, Mearin F. Effect of sacral anterior root stimulator on bowel dysfunction in patients with spinal cord injury. Dis Colon Rectum 2009;52:986–92.
96. Kenefick NJ, Christiansen J. A review of sacral nerve stimulation for the treatment of faecal incontinence. Colorectal Dis 2004; 6:75–80.
97. Jarrett M, Mowatt G, Glazener C, et al. Systematic review of sacral nerve stimulation for faecal incontinence and constipation. Br J Surg 2004;91:1559–69.

References

1. Lewis RW, Fugl-Meyer KS, Bosch R, et al. Epidemiology/risk factors of sexual dysfunction. J Sex Med 2004;1:35–9.
2. Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: classifications and definitions. J Sex Med 2007;4:241–50.
3. Laumann EO, Paik A, Rosen R. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537–44.
4. Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762–74.
5. Foley F, Werner M. Sexuality and intimacy. In: Kalb R, ed. Multiple sclerosis: the questions you ask, the answers you need. New York: Demos Vermonde Press; 2000.
6. Hulter BM, Lundberg PO. Sexual function in women with advanced multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:83–6.
7. Nortvedt MW, Riise T, Myhr KM, et al. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 2001;7:231–5.
8. Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999;5:428–31.
9. Borello-France D, Leng W, O'Leary M, et al. Bladder and sexual function among women with multiple sclerosis. Mult Scler 2004;10:455–61.
10. Aisen M, Sanders A, eds. Sexual dysfunction in neurologic disease: mechanisms of disease and counselling approaches. AUA Update Series Lesson 35; 1998.
11. Annon JS. PLISSIT therapy. In: Corsini R, ed. Handbook of Innovative Psychotherapies. New York: Wiley & Sons; 1981:626–39.
12. Annon JS, Robinson CH. The use of various teaching models in treatment of sexual concerns. In: Piccolo JL, Piccolo LL, eds. Handbook of sexual therapy. New York: Plenum Press; 1978.
13. McBride KE, Rines B. Sexuality and spinal cord injury: a road map for nurses. SCI Nurs 2000;17:8–13.
14. Valleroy ML, Kraft GH. Sexual dysfunction in multiple sclerosis. Arch Phys Med Rehabil 1984;65:125–8.
15. Kirkeby HJ, Poulsen EU, Petersen T, Dorup J. Erectile dysfunction in multiple sclerosis. Neurology 1988;38:1366–71.
16. Staerman F, Guiraud P, Coeurdacier P, et al. Value of nocturnal penile tumescence and rigidity (NPTR) recording in impotent patients with multiple sclerosis. Int J Impot Res 1996;8:241–5.
17. Betts CD, Jones SJ, Fowler CG, Fowler CJ. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain 1994;117(Pt 6):1303–10.
18. Vas CJ. Sexual impotence and some autonomic disturbances in men with multiple sclerosis. Acta Neurol Scand 1969;45:166–82.
19. Witt MA, Grantmyre JE. Ejaculatory failure. World J Urol 1993;11:89–95.
20. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–30.
21. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.
22. Kalichman SC, Rompa D. Sexual sensation seeking and sexual compulsivity scales: reliability, validity, and predicting HIV risk behavior. J Pers Assess 1995;65:586–601.
23. Fowler CJ. The neurology of male sexual dysfunction and its investigation by clinical neurophysiological methods. Br J Urol 1998;81:785–95.
24. Stief CG, Djamilian M, Anton P, et al. Single potential analysis of cavernous electrical activity in impotent patients: a possible diagnostic method for autonomic cavernous dysfunction and cavernous smooth muscle degeneration. J Urol 1991;146:771–6.
25. Jiang XG, Speel TG, Wagner G, Meuleman EJ, Wijkstra H. The value of corpus cavernosum electromyography in erectile dysfunction: current status and future prospect. Eur Urol 2003;43:211–8.
26. Ward-Abel N. Sexuality & MS: a guide for women. Letchworth Garden City, UK: Multiple Sclerosis Trust; 2007.
27. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452–7.
28. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008;53:275–87.
29. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67–85.
30. Clayton AH, Warnock JK, Kornstein SG, et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004;65:62–7.
31. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67:736–46.
32. Saiz-Ruiz J, Montes JM, Ibanez A, et al. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. Hum Psychopharmacol 2005;20:435–40.
33. Lombardi G, Macchiarella A, Cecconi F, Del Popolo G. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. J Sex Med 2009;6:1248–58.
34. Fowler CJ, Miller JR, Sharief MK, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:700–5.
35. Giuliano F, Hultling C, El Masry WS, et al. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. Ann Neurol 1999;46:15–21.
36. Padma-Nathan H, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract 1998;52:375–9.
37. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421–6.
38. Wespes E, Amar E, Hatzichristou D, et al. EAU guidelines on erectile dysfunction. http://www.uroweb.org/fileadmin/tx_eauguidelines/Erectile%20Dysfunction.pdf. 2005:1–28.
39. Hackett G, Kell P, Ralph D, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008;5:1841–65.
40. Gacci M, Del Popolo G, Macchiarella A, et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007;178:2040–3.
41. Brant WO, Bella AJ, Lue TF. Treatment options for erectile dysfunction. Endocrinol Metab Clin North Am 2007;36:465–79.
42. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371–4.
43. Danesh-Meyer HV, Levin LA. Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association? Br J Ophthalmol 2007;91:1551–5.
44. Pavone C, Curto F, Anello G, et al. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2004;172(6 Pt 1):2347–9.
45. Eardley I, Wright P, MacDonagh R, Hole J, Edwards A. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93:1271–5.
46. Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am 2001;28:335–41.
47. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A. Outcome analysis of goal directed therapy for impotence. J Urol 1996;155:1609–12.
48. Hirsch IH, Smith RL, Chancellor MB, et al. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia 1994;32:661–4.
49. Bella AJ, Brock GB. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine 2004;23:149–55.
50. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336:1–7.
51. Fulgham PF, Cochran JS, Denman JL, et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998;160(6 Pt 1):2041–6.
52. Goldstein I, Newman L, Baum N, et al. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol 1997;157:833–9.
53. Carson CC. Penile prostheses: are they still relevant? BJU Int 2003;91:176–7.
54. Claes H, van Hove J, van de Voorde W, et al. Pelvi-perineal rehabilitation for dysfunctioning erections. A clinical and anatomo-physiologic study. Int J Impot Res 1993;5:13–26.
55. Riley AJ. Yohimbine in the treatment of erectile disorder. Br J Clin Pract 1994;48:133–6.
56. Sperling H, Lorenz A, Krege S, Arndt R, Michel MC. An extract from the bark of Aspidosperma quebracho blanco binds to human penile alpha-adrenoceptors. J Urol 2002;168:160–3.
57. Soler JM, Previnaire JG, Plante P, Denys P, Chartier-Kastler E. Midodrine improves ejaculation in spinal cord injured men. J Urol 2007;178:2082–6.
58. Lara LA, Useche B, Ferriani RA, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med 2009;6:30–9.
59. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005–17.
60. Ziaei S, Moaya M, Faghihzadeh S. Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women. Climacteric 2010;13:249–53.
61. Bolour S, Braunstein G. Testosterone therapy in women: a review. Int J Impot Res 2005;17:399–408.
62. Sipski ML, Rosen RC, Alexander CJ, Hamer RM. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000;55:812–5.
63. Dasgupta R, Wiseman OJ, Kanabar G, Fowler CJ, Mikol DD. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004;171:1189–93.
64. Wilson SK, Delk JR, 2nd, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. J Gend Specif Med 2001;4:54–8.
65. Canavan TP, Heckman CD. Dyspareunia in women. Breaking the silence is the first step toward treatment. Postgrad Med 2000;108:149–52, 157–60, 164–6.
66. Ellerkmann RM, Cundiff GW, Melick CF, et al. Correlation of symptoms with location and severity of pelvic organ prolapse. Am J Obstet Gynecol 2001;185:1332–7.
67. Tiefer L, Schuetz-Mueller D. Psychological issues in diagnosis and treatment of erectile disorders. Urol Clin North Am 1995;22:767–73.
68. Stravynski A, Gaudette G, Lesage A, et al. The treatment of sexually dysfunctional men without partners: a controlled study of three behavioural group approaches. Br J Psychiatry 1997;170:338–44.
69. McCarthy BW. Relapse prevention strategies and techniques in sex therapy. J Sex Marital Ther 1993;19:142–6.